Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

Biological Psychiatry

Volumn 74, Issue 4, 2013, Pages 250-256

  Murrough, James W ^a   Perez, Andrew M ^a   Pillemer, Sarah ^a   Stern, Jessica ^a   Parides, Michael K ^a   Aan Het Rot, Marije ^b   Collins, Katherine A ^a   Mathew, Sanjay J ^c,d   Charney, Dennis S ^a   Iosifescu, Dan V ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antidepressant; experimental therapeutics; glutamate; ketamine; major depressive disorder; treatment resistant depression

Indexed keywords

KETAMINE;

ABNORMAL SENSATION; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BLURRED VISION; CLINICAL ARTICLE; DROWSINESS; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VITAL SIGN;

ANTIDEPRESSANT; EXPERIMENTAL THERAPEUTICS; GLUTAMATE; KETAMINE; MAJOR DEPRESSIVE DISORDER; TREATMENT-RESISTANT DEPRESSION;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED;

EID: 84880767967     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.06.022     Document Type: Article

References (38)

1. P.Y. Collins, V. Patel, S.S. Joestl, D. March, T.R. Insel, and A.S. Daar Grand challenges in global mental health Nature 475 2011 27 30
2. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, and D. Warden Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report Am J Psychiatry 163 2006 1905 1917
3. A.J. Rush, M.H. Trivedi, J.W. Stewart, A.A. Nierenberg, M. Fava, and B.T. Kurian Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study Am J Psychiatry 168 2011 689 701
4. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
5. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
6. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial Int J Neuropsychopharmacol 13 2010 71 82
7. J.W. Murrough Ketamine as a novel antidepressant: From synapse to behavior Clin Pharmacol Ther 91 2011 303 309
8. S.J. Mathew Treatment-resistant depression: Recent developments and future directions Depress Anxiety 25 2008 989 992
9. R.C. Shelton, O. Osuntokun, A.N. Heinloth, and S.A. Corya Therapeutic options for treatment-resistant depression CNS Drugs 24 2010 131 161
10. N. Diazgranados, L.A. Ibrahim, N.E. Brutsche, R. Ameli, I.D. Henter, and D.A. Luckenbaugh Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder J Clin Psychiatry 71 2010 1605 1611
11. C.A. Zarate Jr, N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, and A. Cravchik Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial Biol Psychiatry 71 2012 939 946
12. L. Ibrahim, N. Diazgranados, J. Franco-Chaves, N. Brutsche, I.D. Henter, and P. Kronstein Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study Neuropsychopharmacology 37 2012 1526 1533
13. M.L. Phillips, W.C. Drevets, S.L. Rauch, and R. Lane Neurobiology of emotion perception II: Implications for major psychiatric disorders Biol Psychiatry 54 2003 515 528
14. J.W. Murrough, and D.S. Charney Cracking the moody brain: Lifting the mood with ketamine Nat Med 16 2010 1384 1385
15. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, and D.S. Charney Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol Psychiatry 67 2010 139 145
16. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured Clinical Interview for DSM-IV Axis Disorders (SCID) 1995 New York State Psychiatric Institute, Biometrics Research New York
17. H.A. Sackeim The definition and meaning of treatment-resistant depression J Clin Psychiatry 62 Suppl 16 2001 10 17
18. A.J. Rush, C.M. Gullion, M.R. Basco, R.B. Jarrett, and M.H. Trivedi The Inventory of Depressive Symptomatology (IDS): Psychometric properties Psychol Med 26 1996 477 486
19. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br J Psychiatry 134 1979 382 389
20. J.E. Overall, D.R. Gorham, and J.R. Shawver Basic dimensions of change in the symptomatology of chronic schizophrenics J Abnorm Soc Psychol 63 1961 597 602
21. J.D. Bremner, J.H. Krystal, F.W. Putnam, S.M. Southwick, C. Marmar, and D.S. Charney Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) J Trauma Stress 11 1998 125 136
22. R.C. Young, J.T. Biggs, V.E. Ziegler, and D.A. Meyer A rating scale for mania: Reliability, validity and sensitivity Br J Psychiatry 133 1978 429 435
23. J. Levine, and N.R. Schooler SAFTEE: A technique for the systematic assessment of side effects in clinical trials Psychopharmacol Bull 22 1986 343 381
24. R.B. Price, M.K. Nock, D.S. Charney, and S.J. Mathew Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression Biol Psychiatry 66 2009 522 526
25. G.L. Larkin, and A.L. Beautrais A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department Int J Neuropsychopharmacol 14 2011 1127 1131
26. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, and L. Ritz Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice Am J Psychiatry 163 2006 28 40
27. A. Szegedi, M.J. Müller, I. Anghelescu, C. Klawe, R. Kohnen, and O. Benkert Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression J Clin Psychiatry 64 2003 413 420
28. V. Henkel, F. Seemuller, M. Obermeier, M. Adli, M. Bauer, and C. Mundt Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression J Affect Disord 115 2009 439 449
29. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
30. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
31. E. Beurel, L. Song, and R.S. Jope Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice Mol Psychiatry 16 2011 1068 1070
32. R.J. Schwartzman, G.M. Alexander, J.R. Grothusen, T. Paylor, E. Reichenberger, and M. Perreault Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study Pain 147 2009 107 115
33. K. Wolff, and A.R. Winstock Ketamine: from medicine to misuse CNS Drugs 20 2006 199 218
34. E.B. Perry Jr, J.A. Cramer, H.S. Cho, I.L. Petrakis, L.P. Karper, and A. Genovese Psychiatric safety of ketamine in psychopharmacology research Psychopharmacology (Berl) 192 2007 253 260
35. J.W. Olney, J. Labruyere, and M.T. Price Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs Science 244 1989 1360 1362
36. J.W. Olney, J. Labruyere, G. Wang, D.F. Wozniak, M.T. Price, and M.A. Sesma NMDA antagonist neurotoxicity: mechanism and prevention Science 254 1991 1515 1518
37. Y. Liao, J. Tang, M. Ma, Z. Wu, M. Yang, and X. Wang Frontal white matter abnormalities following chronic ketamine use: A diffusion tensor imaging study Brain 133 2010 2115 2122
38. Y. Liao, J. Tang, P.R. Corlett, X. Wang, M. Yang, and H. Chen Reduced dorsal prefrontal gray matter after chronic ketamine use Biol Psychiatry 69 2011 42 48